Sanofi, a prominent company in the bio-tech market, has recently undergone several significant changes and experienced varied successes. Paris-based pharmaceutical giant announced a four-year PIONEER Data showcasing sustained benefits and long-term safety of
AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis. In the recent developments, Paul Hudson was replaced as CEO, with Belén Garijo stepping into the role. In line with its growth strategy, the company announced expansion plans in India, planning to increase its workforce to over 4,500 employees. Placing significant emphasis on AI, the new CEO predicted a significant reshaping of pharma in 2026 due to enterprise AI adoption.
Dupixent, a collaboration product of Sanofi and Regeneron, was recommended for EU approval for treating chronic spontaneous urticaria in children. Moreover, Sanofi's new sleeping sickness pill was approved, opening possibilities for its use in Africa. In a surprising turn of events, speculation regarding a Sanofi takeover sent Ocular’s stock skyrocketing. However, Sanofi shares fell 6% after a setback for MS drug tolebrutinib. The company also faced some hurdles as Sanofi's genetic disorder drug showed mixed results in late-stage trials.
Sanofi News Analytics from Tue, 10 Jun 2025 16:13:51 GMT to Sat, 28 Feb 2026 14:45:00 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -3
